These studies indicate that targeting the CXCL12/CXCR4 axis may be a viable therapeutic strategy to improve the antitumor immune response in a spectrum of cancer types, both on its own and in combination with immune checkpoint blockade. The gene discussed is CXCL12; the disease is cancer.